加味金匮肾气丸对哮喘大鼠气道炎症的缓解作用及其机制研究

蒋朱秀; 郑小伟<sup>*</sup>; 江劲; 李敏静; 蔡宛如

引用本文:	蒋朱秀,郑小伟,江劲,李敏静,蔡宛如.加味金匮肾气丸对哮喘大鼠气道炎症的缓解作用及其机制研究[J].中国现代应用药学,2015,32(8):932-935.
	JIANG Zhuxiu,ZHENG Xiaowei,JIANG Jin,LI Minjing,CAI Wanru.Research of Modified Jinkui Shenqi Pills on Eosinophils and Chemokine of Asthmatic Rats[J].Chin J Mod Appl Pharm(中国现代应用药学),2015,32(8):932-935.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 2274次下载 1215次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
加味金匮肾气丸对哮喘大鼠气道炎症的缓解作用及其机制研究
蒋朱秀¹, 郑小伟², 江劲¹, 李敏静¹, 蔡宛如¹
1.浙江中医药大学附属第二医院，杭州 310005;2.浙江中医药大学，杭州 310053

摘要:

目的研究加味金匮肾气丸对支气管哮喘大鼠气道炎症的缓解作用及其机制。方法 60只健康大鼠随机分成正常对照组、模型组、地塞米松组、加味金匮肾气丸低、中、高剂量组，以卵白蛋白(OVA)致敏激发制备哮喘模型，观察各组大鼠肺组织病理学的改变，测定肺泡灌洗液中嗜酸性粒细胞(eosinophils，EOS)计数和肺组织中胸腺活化调节趋化因子(thymus activation regulated chemokine，TARC)含量。结果加味金匮肾气丸能减轻哮喘大鼠模型的喘息症状、降低支气管肺泡灌洗液中EOS计数和肺组织中TARC的含量，结果均有显著性差异(P<0.01或P<0.05)。病理组织学检查结果显示，模型组大鼠肺组织支气管黏膜上皮细胞以及杯状细胞增生，肺泡内有分泌物和炎性细胞浸润，官腔狭窄；各药物组病理改变均显著减轻。结论加味金匮肾气丸治疗支气管哮喘的机制可能是通过抑制TARC和减少EOS浸润而实现的。

关键词: 哮喘胸腺活化调节趋化因子嗜酸性粒细胞加味金匮肾气丸

DOI：

分类号:

基金项目:浙江省中医药科技计划项目(2007CB158)；浙江省名老中医专家传承工作室建设经费资助项目(GZS2012012)

Research of Modified Jinkui Shenqi Pills on Eosinophils and Chemokine of Asthmatic Rats

JIANG Zhuxiu¹, ZHENG Xiaowei², JIANG Jin¹, LI Minjing¹, CAI Wanru¹

1.The Second Affiliated Hospital of Zhejiang University of Chinese Medicine, Hangzhou 310005, China;2.Zhejiang University of Chinese Medicine, Hangzhou 310053, China

Abstract:

OBJECTIVE To observe the effect of modified Jinkui Shenqi pills, on the thymus and activation regulated chemokine(TARC) and eosinophile(EOS) count in rats with asthmatic. METHODS Sixty rats were randomly divided into 6 groups: the normal group, the model group, the dexamethasone group, the modified low, medium and high dose groups. The chronic asthmatic model was established by repeated inhalation of ovalbumin. The morphological change of bronchial and lung tissues, the number of EOS in bronchoalveolar lavage fluid and the content of lung tissue TARC were observed. RESULTS Jinkui Shenqi pills obviously improved the asthma degree, decreased the content of TARC and EOS(P<0.05 or P<0.01). Pathological results revealed that the bronchial mucosa epithelial cells and goblet cells hyperplasia, alveolar contains secretions and inflammatory cells infiltration, luminal stenosis in the model group. And these changes were released obviously in the modified Jinkui Shenqi pills groups. CONCLUSION Modified Jinkui Shenqi pills can treat asthma possibly by inhibiting TARC and EOS.

Key words: asthma thymus activation regulated chemokine eosinophile modified Jinkui Shenqi pills